Alterity Therapeutics (ADR) (ATHE)
Develops ATH434, a clinical candidate for multiple system atrophy and related Parkinsonian disorders.
Something off on this page? Send us feedback.
Advances ATH434, a small-molecule clinical candidate for multiple system atrophy and related Parkinsonian disorders. The Melbourne-based company has no approved product described in its latest filing and depends on clinical, regulatory, and financing progress.
Advances ATH434, a small molecule designed to inhibit pathological protein aggregation and restore normal iron balance in the brain. The clinical program focuses on multiple system atrophy and related Parkinsonian disorders, following earlier Prana-era work on Alzheimer’s and Huntington’s disease; the PBT2 program was ended after a Phase 2 trial missed its primary endpoint.
Operates as a clinical-development enterprise rather than a commercial drug seller, with most staff in research and development. Its ordinary shares have an Australian primary listing while ADSs trade on Nasdaq, and its work is shaped by clinical execution, regulatory engagement, and financing milestones. No approved product is described in the latest reviewed filing.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 15, 2026 | Lake Street | Initiate | Rating: —Target: — | Target: $10 |
| Aug 11, 2026 | UBS | Target | Target: — | Target: $12 |
| Aug 11, 2026 | Craig-Hallum | Initiate | Rating: —Target: $12 | Target: $2 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $26.3M · Total debt $136.3K · Total assets $32.4M · Shareholders' equity $30.1M
- Revenue
- $0
- Operating income
- −$11.0M
- Net income
- −$9.8M
Reported in AUD, converted at the latest exchange rate
No dividends on record.
| Institutions | 2.18% | 394.5K ADS | |
|---|---|---|---|
| 22 holders · as of Jun 30, 2026 | |||
| Insiders | 8.53% | 1.55M ADS | |
| 4 holders · as of Sep 8, 2026 | |||
| Other | 89.29% | 16.19M ADS | |
| remainder | |||
18.13M ADS (1 ADS = 12 ordinary shares) as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
David Allen StamlerInsiderdirector, officer: Chief Executive Officer | 6.14% | 11.69M ordinary · 139,258 ADS | filed Apr 15, 2026 |
Lawrence Bernard GozlanInsiderdirector | 2.09% | 4.55M ordinary | filed Apr 10, 2026 |
Twin Lakes Capital Management, LLCInstitution | 0.77% | 139,258 ADS | as of Jun 30, 2026 |
Morgan StanleyInstitution | 0.35% | 63,065 ADS | as of Jun 30, 2026 |
Greenleaf TrustInstitution | 0.34% | 62,000 ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 31, 2026 | Peter Ashley Marks | director | +95,240 | $0.5000 |
| Aug 31, 2026 | David Allen Stamler | director, officer: Chief Executive Officer | +47,620 | $0.5000 |
- Teva (ADR)
Recruiting oral MSA α-synuclein-oligomer program
- Ionis Pharmaceuticals
Recruiting intrathecal RNA therapy for MSA alpha-synuclein
- ProMIS Neurosciences
Preclinical α-synuclein antibody program for MSA and PD
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Alterity Therapeutics (ADR) | $3.78 | −0.13% | $64.0M | — | — | — | −80.5% |
| Teva (ADR) | $39.06 | −1.16% | $46.03B | 65.9 | 13.9 | 2.7 | −0.8% |
| Ionis Pharmaceuticals | $43.96 | −3.91% | $7.60B | — | — | 8.7 | −40.7% |
| ProMIS Neurosciences | $13.31 | −1.99% | $17.8M | — | — | — | — |
| Median | 65.9 | 13.9 | 5.7 | −20.8% |